Private NIH Meeting Decides Fate of Heart Research Funding
Published Date: 3/17/2025
Notice
Summary
The National Heart, Lung, and Blood Institute is holding a private virtual meeting on April 16-17, 2025, to review grant applications. This meeting affects researchers seeking funding and keeps sensitive info safe. No public access means they’re protecting personal and trade secrets while deciding who gets money to support important health research.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Closed Grant Review Meeting
The National Heart, Lung, and Blood Institute will hold a closed, virtual meeting on April 16-17, 2025 (9:00 a.m. to 6:00 p.m.) to review and evaluate grant applications. The meeting is closed to the public under 5 U.S.C. 552b(c)(4) and 552b(c)(6).
Applicant Confidentiality Protected
The meeting is closed because discussing grant applications could disclose confidential trade secrets, patentable material, or personal information about applicants. That protection is in accordance with 5 U.S.C. 552b(c)(4) and 552b(c)(6).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2025-04207, National Heart, Lung, and Blood Institute; Notice of Closed Meeting
The National Heart, Lung, and Blood Institute is holding a closed virtual meeting on April 22, 2025, to review and decide on grant applications. This meeting affects researchers seeking funding for heart, lung, and blood health projects and keeps sensitive info private. No public access or money changes are announced, but important funding decisions will be made behind the scenes.
Next: 2025-04209, National Heart, Lung, and Blood Institute; Notice of Closed Meetings
The National Heart, Lung, and Blood Institute is holding secret virtual meetings in early April 2025 to review important grant applications. These closed sessions protect private info and trade secrets while deciding who gets funding to fight heart and lung diseases. Researchers and organizations applying for grants should watch these dates closely, as funding decisions could impact their projects and budgets.